scholarly journals TGFBI Protein Is Increased in the Urine of Patients with High-Grade Urothelial Carcinomas, and Promotes Cell Proliferation and Migration

2019 ◽  
Vol 20 (18) ◽  
pp. 4483 ◽  
Author(s):  
Kerstin Lang ◽  
Selcan Kahveci ◽  
Nadine Bonberg ◽  
Katharina Wichert ◽  
Thomas Behrens ◽  
...  

Here, we discovered TGFBI as a new urinary biomarker for muscle invasive and high-grade urothelial carcinoma (UC). After biomarker identification using antibody arrays, results were verified in urine samples from a study population consisting of 303 patients with UC, and 128 urological and 58 population controls. The analyses of possible modifying factors (age, sex, smoking status, urinary leukocytes and erythrocytes, and history of UC) were calculated by multiple logistic regression. Additionally, we performed knockdown experiments with TGFBI siRNA in bladder cancer cells and investigated the effects on proliferation and migration by wound closure assays and BrdU cell cycle analysis. TGFBI concentrations in urine are generally increased in patients with UC when compared to urological and population controls (1321.0 versus 701.3 and 475.6 pg/mg creatinine, respectively). However, significantly increased TGFBI was predominantly found in muscle invasive (14,411.7 pg/mg creatinine), high-grade (8190.7 pg/mg) and de novo UC (1856.7 pg/mg; all p < 0.0001). Knockdown experiments in vitro led to a significant decline of cell proliferation and migration. In summary, our results suggest a critical role of TGFBI in UC tumorigenesis and particularly in high-risk UC patients with poor prognosis and an elevated risk of progression on the molecular level.

2020 ◽  
Author(s):  
Wenxiang wang ◽  
Wenqiang Fan ◽  
Yuxia Gao ◽  
Yu Liu ◽  
Li Li ◽  
...  

Abstract Background In recent years, long noncoding RNAs (lncRNAs) have been reported frequently to play important roles in specific cancers, including high-grade serous ovarian cancer (HGSOC). PVT1 is an important oncogenic lncRNA highly expressed in various cancers. However, little is known about the role of PVT1 in HGSOC and underlying mechanisms. Methods The expression levels of PVT1 and HER2/3 in HGSOC tissue and adjacent normal tissue were determined by qRT-PCR. MTT and transwell assays were used to identify the effects of PVT1 cell proliferation and migration respectively. Dual-luciferase reporter assay and RIP experiment were carried out to verify target genes of PVT1. ChIP experiment was used to identify that HER2 was transcription factor of PVT1. Results Our results showed that PVT1 expression was up-regulation in human HGSOC specimens and promoted ovarian cancer cell proliferation and migration. We further validated that HER2 was a direct transcription factor for facilitating PVT1 expression. In return, PVT1 enhanced HER2 transcript stability. Moreover, bioinformatics analysis and dual luciferase reporter assay results uncovered that PVT1 functioned as a competing endogenous RNA (ceRNA) for miR-1301-3p to promote cell proliferation and migration by increasing HER3 expression. Conclusions Taken together, our results showed that PVT1, controlled by HER2, elevated HER2 and HER3 expression to promote HGSOC progression. Thus, PVT1 can be regarded as a vital diagnostic biomarker for HGSOC and a potential novel therapeutic target.


2020 ◽  
Author(s):  
Lungwani Muungo

ADP ribosylation factor GTPase-activating protein 3 (ARFGAP3) is a GTPase-activating protein that associates with the Golgiapparatus and regulates the vesicular trafficking pathway. In the present study, we examined the contribution of ARFGAP3 toprostate cancer cell biology. We showed that ARFGAP3 expression was induced by 100 nM of dihydrotestosterone (DHT) atboth the mRNA and protein levels in androgen-sensitive LNCaP cells. We generated stable transfectants of LNCaP cells withFLAG-tagged ARFGAP3 or a control empty vector and showed that ARFGAP3 overexpression promoted cell proliferation andmigration compared with control cells. We found that ARFGAP3 interacted with paxillin, a focal adhesion adaptor protein thatis important for cell mobility and migration. Small interfering RNA (siRNA)-mediated knockdown of ARFGAP3 showed thatARFGAP3 siRNA markedly reduced LNCaP cell growth. Androgen receptor (AR)-dependent transactivation activity on prostatespecificantigen (PSA) enhancer was synergistically promoted by exogenous ARFGAP3 and paxillin expression, as shown byluciferase assay in LNCaP cells. Thus, our results suggest that ARFGAP3 is a novel androgen-regulated gene that can promoteprostate cancer cell proliferation and migration in collaboration with paxillin.


Sign in / Sign up

Export Citation Format

Share Document